Abstract
The antitumor effect of the combined administration with recombinant human interleukin-2 (rIL-2) and sizofiran (SPG), a single glucan of Shizophyllum commune Fries, was studied in vivo in C57BL/6 mice intraperitoneally inoculated with EL-4 lymphoma. The effect was evaluated by a) comparing the survival time of the mice, b) analysis of the intraperitoneal cell population in Giemsa-stained specimens, c) surface marker analysis of peritoneal exudative cells with flow cytometry, d) cytotoxic assay of cells against EL-4 and Yac-1 lymphoma, and e) elimination of some cell populations by monoclonal antibodies, to identify the antitumor-effector cells showing cytotoxic activity. The survival of mice given both rIL-2 and SPG was significantly longer than the control mice or those given SPG alone or rIL-2 alone. It was demonstrated that the administration of SPG and/or rIL-2 to the EL-4 lymphoma-bearing mice activated immune-response cells in the peritoneal cavity such as T lymphocytes, NK cells, or macrophages, which might be effective in reducing lymphoma cells. The combination of rIL-2 and SPG administration appears to activate the antitumor- immune response at the tumor site more effectively than when either agent was administered alone.
Similar content being viewed by others
Abbreviations
- SPG:
-
sizofiran
- NK cell:
-
natural killer cell
- PEC:
-
peritoneal exudate cell
- LAK cell:
-
lymphokine activated killer cell
- TIL:
-
tumor infiltrate lymphocyte
References
Chen JT, Hasumi K. Activation of peritoneal macrophages in patients with gynecological malignancies by sizofiran and recombinant interferon-gamma. Biotherapy 1993; 6: 189–94.
Ghose T, Guclu A, Tai J, Mammen M, Norvell ST. Immunoprophylaxis and immunotherapy of EL4 lymphoma. Europ. J. Cancer 1977; 13: 925–935.
Ota T, Tanino M, Kohno H, Funamoto H, Odashima S. Isolation and Characterization of a low metastatic variant from EL-4 mouse T-lymphoma. Clin. Exp. Metastasis 1992; 10: 297–308.
Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 1978; 120: 2027–2032.
Stadler BM, Dougherty SF, Farrar JJ, Oppenheim JJ. Relationship of cell cycle to recovery of IL-2 activity from human mononuclear cells, human and mouse T cell lines. J. Immunol. 1981; 127: 1936–1940.
Morgan DA, Rusetti FW, Gallo RC. Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 1976; 192: 1007–8.
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocyte. J Exp Med 1982; 155: 1823–41.
Sugawara I, Lee KC, Wong M. Schizophyllan(SPG)-treated macrophages and anti-tumor activities against syngeneic and allogeneic tumor cells: I.Characteristics of SPG-treated macrophages. Cancer Immunol Immunother 1984; 16: 137–44.
Tsuchiya Y, Yamamoto M, Igarashi M, Suzuki R, Kumagai K. Study on immunomodulating activity of an antitumor glucan, sizofiran at tumoral factor level. Clin Immunol 1986; 18: 575–84.
Tsuchiya Y, Igarashi M, Inoue M, Kumagai K. Cytokine-related immunomodulating activities of an anti-tumor glucan, sizofiran (SPG). J Pharmacobio-Dyn 1989; 12: 616–25.
Ho RL, Maccubbin DL, Ujhaezy P, Zaleskis G, Eppolito C, Mihich E, Ehrke MJ. Immunological Responses Critical to the Therapeutic Effects of Adriamycin Plus Interleukin 2 in C57BL/6 Mice bearing syngeneic EL-4 Lymphoma, Oncol Res 1993; 5: 363–72.
Hanna N, Fidler IJ. Role of natural killer cells in the destruction of circulating tumor emboli. J. natn. Cancer Inst. 1980; 65: 801–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kano, Y., Kakuta, H. & Hashimoto, J. Augmentation of antitumor effect by combined administration with interleukin-2 and sizofiran, a single glucan, on murine EL-4 lymphoma. Biotherapy 9, 241–247 (1996). https://doi.org/10.1007/BF02620737
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02620737